{
  "docId": "019de072-1a15-7369-8097-68fb5b1d5017",
  "docSlug": "de0c004f3134112f269aa7aa17f1a1f3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 39,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a three-column layout to detail clinical and commercial status for three drugs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1a15-7369-8097-68fb5b1d5017/26",
  "deckHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017",
  "deckJsonHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017.json",
  "deckAnchorHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.12,
        "x": 0.21,
        "y": 0.735
      },
      "kind": "image",
      "text": "Evusheld product packaging",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c348016-1fb5-412c-bee8-08ee5dba61f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.12,
        "x": 0.51,
        "y": 0.745
      },
      "kind": "image",
      "text": "Vaxzevria product packaging",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb4084ef-17b1-4330-9447-a8122ab9d833",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.36,
        "y": 0.23
      },
      "kind": "list",
      "text": "Vaxzevria: Clinical and real-world evidence supports use as booster; 2.5bn doses supplied in 2021; Boosts immune response against Omicron; Retains neutralising activity after two-doses; Vaxzevria and AZD2816 generated similar immune response",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2084e860-affa-4454-8983-23748a3be9f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.67,
        "y": 0.23
      },
      "kind": "list",
      "text": "eplontersen: ATTR Collaboration with Ionis Pharmaceuticals; ATTR: misfolded protein and accumulation as amyloid fibrils; Phase III trials: CARDIO-TTransform and NEURO-TTransform",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32cf0a36-f4da-45b8-b3d0-c1788c5cae5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "Evusheld: Only long-acting antibody combination shown to prevent and treat COVID-19; Authorised in eight countries; Retains neutralising activity against Omicron; US agreements for 1.2m doses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "830fd860-b5e9-48fa-9aa2-933feeae91da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Nature... 2. Includes doses shipped... 3. UK Health Security Agency... 4. The Lancet... 5. Interim results...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53d980ba-18d3-4385-8724-9dd81ce88495",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Four NMEs approved in 2021: Saphnelo, Tezspire, Evusheld and Vaxzevria",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9278da77-88bf-48d8-ac0e-0b4516be019e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.68,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals: R&D pipeline highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d08e18a-564e-4ed8-b872-2b185a71341a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "bcbc8d94-cf78-4a30-a47f-5c33aed5b12c",
      "evidence": "list/bullet: Vaxzevria: Clinical and real-world evidence supports use as booster; 2.5bn doses supplied in 2021; Boosts immune response against Omicron; Retains neutralising activity after two-doses; Vaxzevria and AZD2816",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 26,
      "beatId": "aad1cb9b-557b-4e95-ba5a-dc0050f283ae",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The closing remarks and Q&A session prompt action from the audience.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 26,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f69dbb94-83a9-490b-bc96-5831ed386c14",
      "evidence": "The presentation implies that not investing in the pipeline would mean missing out on growth opportunities.",
      "position": 1,
      "objective": "What are the consequences of not investing in AstraZeneca's pipeline?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}